<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02596256</url>
  </required_header>
  <id_info>
    <org_study_id>AHEAD-301</org_study_id>
    <nct_id>NCT02596256</nct_id>
  </id_info>
  <brief_title>Apatinib Plus Docetaxel Versus Docetaxel as Second-line Treatment in Advanced Gastric Cancer (AHEAD-301)</brief_title>
  <official_title>Apatinib Plus Docetaxel Versus Docetaxel as Second-line Treatment in Advanced Gastric Cancer Stage II Randomized Controlled Clinical Studies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese PLA General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Apatinib plus docetaxel versus docetaxel as second-line treatment in advanced gastric cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial investigated the safety and efficacy of apatinib plus docetaxel, as a treatment&#xD;
      option for heavily pretreated patients with advanced gastric cancer.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">February 2019</completion_date>
  <primary_completion_date type="Anticipated">February 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Apatinib Mesylate Tablets (500 mg qd p.o.) and Docetaxel (60mg/m2 i.v. d1 q21d)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>contrast group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Docetaxel (60mg/m2, i.v. d1 q21d)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apatinib</intervention_name>
    <description>Apatinib (500 mg qd p.o.) until disease progression or intolerable toxicity</description>
    <arm_group_label>control group</arm_group_label>
    <other_name>ATAN</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Docetaxel (60 mg/m2 qd d1 q3w i.v.) until disease progression or intolerable toxicity</description>
    <arm_group_label>contrast group</arm_group_label>
    <arm_group_label>control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age: more than 18 years old, male or female;&#xD;
&#xD;
          2. Pathologically diagnosed with advanced gastric cancer (including adenocarcinoma of the&#xD;
             gastroesophageal junction) with measurable metastases outside the stomach (measuring ≥&#xD;
             10mm on spiral computed tomography(CT) scan, satisfying the criteria in Response&#xD;
             Evaluation Criteria In Solid Tumors (RECIST) 1.1);&#xD;
&#xD;
          3. Failure of prior therapy (during or after treatment) in patients who have received at&#xD;
             first line chemotherapy regimens(platinum - based regimens);&#xD;
&#xD;
          4. Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0-1;&#xD;
&#xD;
          5. Major organ function has to meet the following criteria; (1) For results of blood&#xD;
             routine test and biochemical tests:&#xD;
&#xD;
               1. Hemoglobin (HB) ≥ 80g / L,&#xD;
&#xD;
               2. ANC ≥ 1.5 × 109 / L,&#xD;
&#xD;
               3. PLT ≥ 90 × 109 / L,&#xD;
&#xD;
               4. ALT and AST ≤ 2.5 × ULN, liver metastases, if any, the ALT and AST≤5 × ULN,&#xD;
&#xD;
               5. Bilirubin ≤ 1.5 times the upper limit of normal (ULN),&#xD;
&#xD;
               6. Serum creatinine ≤ 1.5 times the upper limit of normal (ULN),&#xD;
&#xD;
               7. Serum albumin ≥ 30g / L;&#xD;
&#xD;
          6. An expected survival of ≥ 3 months;&#xD;
&#xD;
          7. Pregnancy test (serum or urine) has to be performed for woman of childbearing age&#xD;
             within 7 days before enrolment and the test result must be negative. They shall take&#xD;
             appropriate methods for contraception during the study until the 8th week post the&#xD;
             last administration of study drug. For men, (previous surgical sterilization&#xD;
             accepted), shall agree to take appropriate methods of contraception during the study&#xD;
             until the 8th week post the last administration of study drug;&#xD;
&#xD;
          8. Patient has to voluntarily join the study and sign the Informed Consent Form for the&#xD;
             study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Confirmed that apatinib and/or its accessories allergy;&#xD;
&#xD;
          2. Subjects with poor-controlled arterial hypertension (systolic blood pressure&gt; 140 mmHg&#xD;
             and diastolic blood pressure &gt; 90 mm Hg) despite standard medical management; Coronary&#xD;
             heart disease greater than Class Ⅰ; Ⅰ-level arrhythmia (including QT interval&#xD;
             prolongation, for man ≥ 450 ms, for woman ≥ 470 ms) together with Class Ⅰ cardiac&#xD;
             dysfunction; Patients with positive urinary protein;&#xD;
&#xD;
          3. Factors that could have an effect on oral medication (such as inability to swallow,&#xD;
             chronic diarrhea and intestinal obstruction);&#xD;
&#xD;
          4. Subjects with high gastrointestinal bleeding risk, including the following conditions:&#xD;
             local active ulcer lesions with positive fecal occult blood test (++); history of&#xD;
             black stool, or vomiting blood in the past 2 months;unresected primary lesion in&#xD;
             stomach with positive fecal occult blood test (+), ulcerated gastric carcinoma with&#xD;
             massive alimentary tract bleeding risk judged by PIs based on gastric endoscopy&#xD;
             result;&#xD;
&#xD;
          5. Abnormal Coagulation (INR&gt;1.5、APTT&gt;1.5 UNL), with tendency of bleed;&#xD;
&#xD;
          6. Associated with CNS (central nervous system) metastases;&#xD;
&#xD;
          7. Pregnant or lactating women;&#xD;
&#xD;
          8. Pts with other malignant tumor within 5 years;&#xD;
&#xD;
          9. With psychotropic drug abuse history and can't get rid of or mental disorder patients;&#xD;
&#xD;
         10. Participated in other clinical trials within 4 weeks;&#xD;
&#xD;
         11. Pts received VEGFR inhibitor treatment(i.e. sorafenib, sunitinib);&#xD;
&#xD;
         12. Any other condition that might place the patient at undue risk or preclude a patient&#xD;
             from completing the study;&#xD;
&#xD;
         13. Other conditions regimented at investigators' discretion.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100853</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <study_first_submitted>November 2, 2015</study_first_submitted>
  <study_first_submitted_qc>November 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2015</study_first_posted>
  <last_update_submitted>April 13, 2018</last_update_submitted>
  <last_update_submitted_qc>April 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese PLA General Hospital</investigator_affiliation>
    <investigator_full_name>Dai, Guanghai</investigator_full_name>
    <investigator_title>Department Director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Apatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

